Personal profile
Research interests
Dr. Arati Sharma’s research is focused on melanoma, the most aggressive and metastatic form of skin cancer. Despite one American dying of melanoma every hour, there is no effective long-term treatment for patients' suffering from the advanced stages of the disease.
To be able to effectively treat melanomas, one must understand the biology of melanoma, proteins and signaling pathways involved in melanoma progression and development. In this respect, very few globally important melanoma causing genes or pathways have been identified, and it is only with this knowledge that more effective treatments to repair the defects that are seen in melanoma cells can be tailored and developed.
Dr. Sharma's laboratory has been focused on process of target identification and validation, chemopreventive and chemotherapeutic agent development and elucidating the mechanism of action.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Projects
- 2 Finished
-
Establishing bioactive serum and toxicity levels for Nanolipolee-007
Sharma, A. (PI) & Sharma, A. (CoPI)
9/26/12 → 1/31/14
Project: Research project
-
Chemopreventive Efficacy of Plumbagin in Melanoma
Sharma, A. K. (PI) & Sharma, A. (CoPI)
7/7/09 → 6/30/10
Project: Research project
-
An Overview of the Mechanisms of HPV-Induced Cervical Cancer: The Role of Kinase Targets in Pathogenesis and Drug Resistance
Karnik, M., Tulimilli, S. R. V., Anantharaju, P. G., Bettadapura, A. D. S., Natraj, S. M., Mohideen, H. S., Dovat, S., Sharma, A. & Madhunapantula, S. R. V., Jan 2026, In: Cancers. 18, 2, 318.Research output: Contribution to journal › Review article › peer-review
Open Access -
Critical roles of IKAROS and HDAC1 in regulation of heterochromatin and tumor suppression in T-cell acute lymphoblastic leukemia
Ding, Y., He, B., Bogush, D., Schramm, J., Singh, C., Dovat, K., Randazzo, J., Tukaramrao, D., Hengst, J., Annageldiyev, C., Kudva, A., Desai, D., Sharma, A., Spiegelman, V. S., Huang, S., Viet, C. T., Dorsam, G., Saulnier Scholler, G., Broach, J. & Yue, F. & 1 others, , Aug 2025, In: Leukemia. 39, 8, p. 2010-2020 11 p.Research output: Contribution to journal › Article › peer-review
Open Access -
HoxBlinc lncRNA reprograms CTCF-independent TADs to drive leukemic transcription and HSC dysregulation in NUP98-rearranged leukemia
Hamamoto, K., Zhu, G., Lai, Q., Lesperance, J., Luo, H., Li, Y., Nigam, N., Sharma, A., Yang, F. C., Claxton, D., Qiu, Y., Aplan, P. D., Xu, M. & Huang, S., Apr 1 2025, In: Journal of Clinical Investigation. 135, 7, e184743.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Scopus citations -
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes
Paudel, B. B., Tan, S. F., Fox, T. E., Ung, J., Golla, U., Shaw, J. J. P., Dunton, W., Lee, I., Fares, W. A., Patel, S., Sharma, A., Viny, A. D., Barth, B. M., Tallman, M. S., Cabot, M., Garrett-Bakelman, F. E., Levine, R. L., Kester, M., Feith, D. J. & Claxton, D. & 2 others, , Mar 12 2024, In: Blood Advances. 8, 5, p. 1137-1142 6 p.Research output: Contribution to journal › Letter › peer-review
Open Access7 Link opens in a new tab Scopus citations -
From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies
Golla, U., Patel, S., Shah, N., Talamo, S., Bhalodia, R., Claxton, D., Dovat, S. & Sharma, A., Oct 2024, In: Cancers. 16, 20, 3454.Research output: Contribution to journal › Review article › peer-review
Open Access8 Link opens in a new tab Scopus citations